Website of the organizer - www.sympomed.pl

Place:
Online
Date:
07.10 - 09.10 / 2021

14th International Cardiovascular Reasearch Meeting

Conference under the auspices of the Bydgoszcz Chapter of the Polish Cardiac Society

Live broadcast

Here you will find the live broadcast window after registering to the Event and login to the website.

The broadcast will start here 20 minutes before the planned start of the Event.

SCIENTIFIC PROGRAMME

We invite you to familiarize yourself with the details of the program.

09:15 - 09:20
Opening speech

Jacek Kubica

09:20 - 09:40
Coronary revascularization plus medical therapy or medical therapy alone in elective patients with chronic coronary syndrome (Lecture of the day)

Eliano P. Navarese

09:40 - 09:45
Break
09:45 - 11:00
SESSION 1
09:45 - 10:00
Reduced hospital admissions and increased mortality for acute Heart Failure during COVID-19 pandemic in Poland: a multicentre study (HF-COV-SIRIO 6 study)

Małgorzata Ostrowska

10:00 - 10:15
Predictors of in-hospital clinical outcome in COVID-19 patients

Klaudyna Grzelakowska

10:15 - 10:30
Determinants of anti-SARS-CoV-2 antibodies after vaccination

Magdalena Krintus

10:30 - 10:45
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the COVID-19 (The IMPACT COVID 19 - SIRIO 5 randomized study)

Jacek Kubica

10:45 - 11:00
DISCUSSION
11:00 - 11:15
Break
11:15 - 12:30
SESSION 2
11:15 - 11:30
Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines

Marco Cattaneo

11:30 - 11:45
Optimal Antithrombotic treatment in COVID-19 Patients

Giuseppe Patti

11:45 - 12:00
Biomarkers of Thrombosis in COVID-19

Diana Gorog

12:00 - 12:15
Aspirin as an Ideal Pharmacologic Therapy for COVID-19

Udaya Tantry

12:15 - 12:30
DISCUSSION
12:30 - 12:45
Break
12:45 - 14:15
SESSION 3
12:45 - 13:00
Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition

Paul A. Gurbel

13:00 - 13:15
Ethnic difference of thrombogenicity in patients with coronary artery disease

Young-Hoon Jeong

13:15 - 13:30
Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention

Jolanta Siller-Matula

13:30 - 13:45
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Andrzej Budaj

13:45 - 14:00
Mortality risk prediction in patients with cardiogenic shock (The CardShock study)

Salvatore di Somma

14:00 - 14:15
DISCUSSION
14:15 - 16:15
SESSION 4 - ELECTRA trial investigators meeting
09:00 - 09:20
PCSK9 vaccine – a future therapeutic option or illusory hopes (Lecture of the day)

Maciej Banach

09:20 - 09:30
Break
09:30 - 11:00
SESSION 6
09:30 - 09:45
Acute coronary syndromes in elderly patients

Stefano De Servi

09:45 - 10:00
Cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction (The COOL AMI EU Pivotal Trial)

Marko Noc

10:00 - 10:15
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention (The TWILIGHT Trial)

Robert Gil

10:15 - 10:30
Resorbable Magnesium Scaffold in ACS patients

Magdalena Łanocha

10:30 - 10:45
Baseline electrocardiographic predictors of Left Ventricular Remodeling in STEMI

Tomasz Fabiszak

10:45 - 11:00
DISCUSSION
11:00 - 11:15
Break
11:15 - 12:30
SESSION 7
11:15 - 11:30
Rivaroxaban in Peripheral Artery Disease (The VOYAGER PAD Trial)

Marc Bonaca

11:30 - 11:45
Venous Thromboembolism in cancer patients

Adam Torbicki

wykład sponsorowany przez firme Pfizer

11:45 - 12:00
Percutaneous mechanical thrombectomy in patients with high-risk pulmonary embolism and contraindications for thrombolytic therapy

Klemen Steblovnik

12:00 - 12:15
Transcriptomic Profiling of Femoral Veins in Deep Vein Thrombosis in a Porcine Model

Leszek Gromadziński

12:15 - 12:30
DISCUSSION
12:30 - 12:45
Break
12:45 - 14:15
SESSION 8
12:45 - 13:00
NCU-AF: on-line qualification for ablation of atrial fibrillation and left atrial appendage occlusion

Piotr Adamski

13:00 - 13:15
Management of patients with coronary artery disease in Lithuania

Jolita Badariene

13:15 - 13:30
Outcomes of managed care in acute myocardial infarction survivors survivors

Piotr Jankowski

13:30 - 13:45
Determinants of elevated lipid parameters in patients without diagnosed car-diovascular disease - results from the polish arm of the EUROASPIRE V sur-vey

Jakub Ratajczak

13:45 - 14:00
PCSK9 inhibitors in acute coronary syndrome

Miłosz Jaguszewski

14:00 - 14:15
DISCUSSION
14:15 - 14:30
Break
14:30 - 15:45
SESSION 9
14:30 - 14:45
Impact of COVID-19 on clinical outcome in acute coronary syndrome patients

Wojciech Wojakowski

14:45 - 15:00
Renal injury in patients admitted due to Covid-19 – single centre experience

Małgorzata Jasiewicz

15:00 - 15:15
Electrotherapy in the COVID-19 era in Poland

Jarosław Kaźmierczak

15:15 - 15:30
ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors

Marek Postuła

15:30 - 15:45
DISCUSSION
15:45 - 17:00
SIRIO MEDICINE network meeting
09:00 - 09:20
On the Shades of Coronary Calcium and Plaque Instability - (Lecture of the day)

Eloisa Arbustini

09:20 - 09:30
Break
09:30 - 11:00
SESSION 11
09:30 - 09:45
Levosimendan improves the acute course of takotsubo syndrome

Miłosz Jaguszewski

09:45 - 10:00
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Fail-ure and Reduced Ejection Fraction

Jarosław Drożdż

10:00 - 10:15
Multivessel Intervention in Myocardial Infarction with Cardiogenic Shock (CULPRIT-SHOCK Trial Outcomes in the PL-ACS Registry)

Przemysław Trzeciak

10:15 - 10:30
Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis (DEB-Dragon-Registry)

Piotr Niezgoda

10:30 - 10:45
The impact of the COVID-19 pandemic on the functioning of the emergency medical service

Michał Kasprzak

10:45 - 11:00
DISCUSSION
11:00 - 11:15
Closing remarks

Jacek Kubica

Contact

CONTACT 

k.sek@sympomed.pl
 +48 603 770 458

k.sek@sympomed.pl